IXCHIQ Chikungunya vaccine: UK marketing authorisation withdrawn following safety review

• IXCHIQ chikungunya vaccine marketing authorisation withdrawn in UK following CHM safety review, indicating benefit-risk profile no longer favourable
• Clinicians should cease prescribing and counsel patients already vaccinated about implications of this regulatory decision
• Alternative chikungunya prevention measures (vector control, travel advice) should be emphasised for at-risk populations until further guidance issued

Following advice from the Commission on Human Medicines (CHM), the MHRA has concluded that the benefit-risk balance for the IXCHIQ chikungunya vaccine is no longer considered favourable and the UK marketing authorisation has…

ClinicaliQ summarises and contextualises external updates for clinical awareness, then links to the original publisher for the full article and most current context.